After decades of unsuccessful attempts to develop an HIV vaccine—primarily due to the virus’s high mutation rate—scientists at Gilead Pharmaceuticals have developed a novel small molecule drug that prevents HIV infection by disrupting the assembly of HIV capsid proteins, which encapsulate the virus’s genome. Remarkably, since capsid proteins are present in all viruses, this innovative strategy holds the potential to be adapted for preventing other viral diseases!

Lenacapavir